The Credit Card Trademark

Can’t believe Capital One hasn’t taken action again this.

Posted in Uncategorized | Leave a comment

Beyoncé Trademark Suit

blue-ivy-200x250The TTAB denied Beyoncé’s request to seal the date and time of her deposition concerning “her” BLUE IVY CARTER trademark.

The motion for the protective order was denied by the Trademark Trial & Appeal Board, who ruled earlier this week that they didn’t find the arguments about Beyonce’s fears for her family’s safety persuasive.

The singer’s lawyer argued that keeping the details private would “reduce the dangerous pandemonium that so often marks Mrs. Carter’s public appearances.” Of course, a deposition is hardly a “public appearance”.


Posted in Uncategorized | Leave a comment

Eiffel Tower Copyright?

Sharing a photo of the Eiffel Tower by night on social media, without paying for it, could get you into big trouble. Even if it’s just a holiday memento. Ooh la la…


Posted in Uncategorized | Leave a comment

Apple’s GC Retires

apple-logo_318-40184Bruce Sewell, Apple’s’s general counsel since 2009, announced his retirement Friday after eight years as captain of Apple’s legal and security affairs.


Posted in Business of Trademarks, Miscellaneous | Leave a comment

“Naked” Licenses

buying-nakedFailure to exert quality control, or otherwise properly supervise the nature and quality of a licensee’s use of your trademarks, results in what’s known as a “naked license” that can strip your company (or client) of its trademark rights.

Why is quality control by a licensor so important?


Posted in Post-Registration, Trademarks | Leave a comment

CSL Returns…for BMW

bmw-logo-2000-2048x2048It appears that BMW has filed three applications filed by BMW for the trademark CSL in the United States. Filed on 19 April 2017, the marks are M2 CSL, M4 CSL, and M8 CSL.

CSL is an acronym for Coupe Sport Leightbau, or Coupe Sport Lightweight, and has not appeared on a BMW vehicle since 2004, when the M3 CSL spent a single year in production, and was limited to 1,400 units.



Posted in Trademarks, USPTO | Leave a comment

Be Vigilant!

Protecting a brand is not easy; it requires diligence and strategy. Unlike owners of other forms of intellectual property, trademark holders have an affirmative duty to police their trademarks, and can lose trademark rights if they fail to do so.


Posted in Practice Tips, Trademarks | Leave a comment

When Filing Maintenance Documents: Beware!

uspto_modern1613.17(a) Correcting Deficiencies in Affidavits or Declarations Timely Filed Within the Periods Set Forth in § 71(a) of the Act

If the affidavit or declaration is filed during the periods set forth in § 71(a) of the Act (i.e., during the sixth year after the date of registration in the United States, or within one year before the end of any ten-year period after the date of registration in the United States), deficiencies may be corrected, after notification from the Office, within the relevant period without paying a deficiency surcharge, or after the expiration of the relevant period with payment of the deficiency surcharge required by § 71(c) of the Act, 15 U.S.C. § 1141k(c).

Any deficiency must be cured before the end of the relevant filing period set forth in § 71 of the Act or within the set period for response to the Office action, whichever is later. 15 U.S.C. § 1141k(c). If no response is filed, or if the holder does not correct the deficient affidavit or declaration, within this time period, the registration will be cancelled, unless time remains in the grace period under §71(a)(3) of the Act, 15 U.S.C. §1141k(a)(3). If time remains in the grace period, the holder may file a complete new affidavit, with a new fee. See TMEP § 1613.16.

Posted in Post-Registration, Trademark Prosecution, USPTO | Leave a comment

USPTO Considers Submission Limits

The U.S. Patent & Trademark Office is considering setting file size/page limits for proof of use specimens.

Posted in USPTO | Leave a comment

Sanofi, Boehringer to Swap Assets

Sanofi agreed to a €22.8 billion ($25.1 billion) asset swap with Germany’s Boehringer Ingelheim GmbH that purports to boost the French drugmaker’s business in selling over-the-counter drugs.

Sanofi will trade its animal-health business (Merial), valued at €11.4 billion, for Boehringer’s €6.7 billion consumer-health business. Closely-held BI will make a €4.7 billion cash payment to Sanofi.

The deal helps Sanofi CEO Olivier Brandicourt reshape Sanofi whose pharmaceuticals division has suffered declining sales of its best-selling insulin product. It also adds to the company’s growth in the consumer products space.


Posted in Miscellaneous, Pharmaceuticals, Uncategorized | Leave a comment